Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

Cancer and Metastasis Reviews

Volumn 29, Issue 4, 2010, Pages 723-735

  Panigrahy, Dipak ^a,b   Kaipainen, Arja ^c   Greene, Emily R ^a,b   Huang, Sui ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Arachidonic acid; Cancer; Cytochrome P450; EETs; HETEs; Metastasis

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; AUTACOID; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOTOXIC AGENT; EPOXYICOSATRIENOIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HET 0016; HYDROXYICOSATETRAENOIC ACID; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE; LIPID; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPASE A2; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN SYNTHASE; THROMBOXANE; THROMBOXANE A2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; XENOBIOTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SYNTHESIS; GENE EXPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID PEROXIDATION; METABOLITE; METASTASIS; NEOPLASM; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASODILATATION; ANIMAL; ENZYMOLOGY; METABOLISM;

ANIMALS; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 79952196577     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-010-9264-x     Document Type: Review

References (134)

1. Zeldin, D. C. (2001). Epoxygenase pathways of arachidonic acid metabolism. The Journal of Biological Chemistry, 276, 36059-36062.
2. Imig, J. D., & Hammock, B. D. (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nature Reviews. Drug Discovery, 8, 794-805.
3. Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10, 181-193.
4. Roman, R. J. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiological Reviews, 82, 131-185. (Pubitemid 34654217)
5. Fleming, I. (2007). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins & Other Lipid Mediators, 82, 60-67. (Pubitemid 44880162)
6. Spector, A. A., & Norris, A. W. (2007). Action of epoxyeicosatrienoic acids on cellular function. American Journal of Physiology. Cell Physiology, 292, C996-C1012. (Pubitemid 46442641)
7. Hardwick, J. P., Song, B. J., Huberman, E., & Gonzalez, F. J. (1987). Isolation, complementary DNA sequence, and regulation of rat hepatic lauric acid omega-hydroxylase (cytochrome P- 450LA omega). Identification of a new cytochrome P-450 gene family. The Journal of Biological Chemistry, 262, 801-810. (Pubitemid 17005256)
8. Powell, P. K., Wolf, I., Jin, R., & Lasker, J. M. (1998). Metabolism of arachidonic acid to 20-hydroxy-5, 8, 11, 14- eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. The Journal of Pharmacology and Experimental Therapeutics, 285, 1327-1336. (Pubitemid 28277936)
9. Miyata,N.,&Roman, R. J. (2005). Role of 20- hydroxyeicosatetraenoic acid (20-HETE) in vascular system. Journal of Smooth Muscle Research, 41, 175-193. (Pubitemid 41596358)
10. Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D. R., et al. (1999). Cytochrome P450 2 C is an EDHF synthase in coronary arteries. Nature, 401, 493-497. (Pubitemid 29470209)
11. Kaspera, R., & Totah, R. A. (2009). Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opinion on Drug Metabolism & Toxicology, 5, 757-771.
12. Zeldin, D. C., Kobayashi, J., Falck, J. R., Winder, B. S., Hammock, B. D., et al. (1993). Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. The Journal of Biological Chemistry, 268, 6402-6407. (Pubitemid 23099336)
13. Yu, Z., Xu, F., Huse, L. M., Morisseau, C., Draper, A. J., et al. (2000). Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circulation Research, 87, 992-998.
14. Chacos, N., Capdevila, J., Falck, J. R., Manna, S., Martin- Wixtrom, C., et al. (1983). The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Archives of Biochemistry and Biophysics, 223, 639-648. (Pubitemid 13103208)
15. Capdevila, J. H., Harris, R. C., & Falck, J. R. (2002). Microsomal cytochrome P450 and eicosanoid metabolism. Cellular and Molecular Life Sciences, 59, 780-789. (Pubitemid 34628239)
16. Capdevila, J., Chacos, N., Werringloer, J., Prough, R. A., & Estabrook, R. W. (1981). Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proceedings of the National Academy of Sciences of the United States of America, 78, 5362-5366. (Pubitemid 12248586)
17. Capdevila, J., Marnett, L. J., Chacos, N., Prough, R. A., & Estabrook, R. W. (1982). Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proceedings of the National Academy of Sciences of the United States of America, 79, 767-770. (Pubitemid 12160313)
18. Morrison, A. R., & Pascoe, N. (1981). Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proceedings of the National Academy of Sciences of the United States of America, 78, 7375-7378. (Pubitemid 12186143)
19. Oliw, E. H., Lawson, J. A., Brash, A. R., & Oates, J. A. (1981). Arachidonic acid metabolism in rabbit renal cortex. Formation of two novel dihydroxyeicosatrienoic acids. The Journal of Biological Chemistry, 256, 9924-9931. (Pubitemid 12176190)
20. Campbell, W. B., Gebremedhin, D., Pratt, P. F., & Harder, D. R. (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circulation Research, 78, 415-423. (Pubitemid 26072547)
21. Morisseau, C., Goodrow, M. H., Dowdy, D., Zheng, J., Greene, J. F., et al. (1999). Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proceedings of the National Academy of Sciences of the United States of America, 96, 8849-8854. (Pubitemid 29374671)
22. Newman, J. W., Watanabe, T., & Hammock, B. D. (2002). The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/ MS. Journal of Lipid Research, 43, 1563-1578.
23. Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1-18. (Pubitemid 38183957)
24. Nebert, D. W., & Russell, D. W. (2002). Clinical importance of the cytochromes P450. Lancet, 360, 1155-1162. (Pubitemid 35246494)
25. Wang, H., Zhao, Y., Bradbury, J. A., Graves, J. P., Foley, J., et al. (2004). Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Molecular Pharmacology, 65, 1148-1158. (Pubitemid 38543486)
26. Finta, C., & Zaphiropoulos, P. G. (2000). The human CYP2C locus: A prototype for intergenic and exon repetition splicing events. Genomics, 63, 433-438. (Pubitemid 30146677)
27. Waxman, D. J., Chen, L., Hecht, J. E., & Jounaidi, Y. (1999). Cytochrome P450-based cancer gene therapy: Recent advances and future prospects. Drug Metabolism Reviews, 31, 503-522. (Pubitemid 29222675)
28. Nebert, D. W., & Dalton, T. P. (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nature Reviews. Cancer, 6, 947-960. (Pubitemid 44862679)
29. Swanson, H. I., Njar, V. C., Yu, Z., Castro, D. J., Gonzalez, F. J., et al. (2010). Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metabolism and Disposition, 38, 539-544.
30. Lu, H., Chen, C. S., & Waxman, D. J. (2009). Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Therapy, 16, 393-404.
31. Jordan, V. C., & Brodie, A. M. (2007). Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 72, 7-25. (Pubitemid 46037765)
32. Bruno, R. D., & Njar, V. C. (2007). Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. Bioorganic & Medicinal Chemistry, 15, 5047-5060. (Pubitemid 46880385)
33. Moreira, V. M., Salvador, J. A., Vasaitis, T. S., & Njar, V. C. (2008). CYP17 inhibitors for prostate cancer treatment-An update. Current Medicinal Chemistry, 15, 868-899. (Pubitemid 351736409)
34. Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., et al. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 285, 1276-1279. (Pubitemid 29398616)
35. Rosolowsky, M., & Campbell, W. B. (1996). Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochimica et Biophysica Acta, 1299, 267-277.
36. Pozzi, A., Macias-Perez, I., Abair, T., Wei, S., Su, Y., et al. (2005). Characterization of 5, 6- and 8, 9-epoxyeicosatrienoic acids (5, 6- and 8, 9-EET) as potent in vivo angiogenic lipids. The Journal of Biological Chemistry, 280, 27138-27146. (Pubitemid 41040752)
37. Fleming, I. (2007). DiscrEET regulators of homeostasis: Epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends in Pharmacological Sciences, 28, 448-452. (Pubitemid 47376754)
38. Alkayed, N. J., Narayanan, J., Gebremedhin, D., Medhora, M., Roman, R. J., et al. (1996). Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke, 27, 971-979. (Pubitemid 26142944)
39. Amruthesh, S. C., Boerschel, M. F., McKinney, J. S., Willoughby, K. A., & Ellis, E. F. (1993). Metabolism of arachidonic acid to epoxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and prostaglandins in cultured rat hippocampal astrocytes. Journal of Neurochemistry, 61, 150-159. (Pubitemid 23175896)
40. Munzenmaier, D. H., & Harder, D. R. (2000). Cerebral microvascular endothelial cell tube formation: Role of astrocytic epoxyeicosatrienoic acid release. American Journal of Physiology. Heart and Circulatory Physiology, 278, H1163-H1167. (Pubitemid 30235492)
41. Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., & Zeldin, D. C. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. The Journal of Biological Chemistry, 271, 3460-3468. (Pubitemid 26065653)
42. Wu, S., Chen,W.,Murphy, E., Gabel, S., Tomer, K. B., et al. (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. The Journal of Biological Chemistry, 272, 12551-12559. (Pubitemid 27203348)
43. Nakayama, K., Nitto, T., Inoue, T., & Node, K. (2008). Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sciences, 83, 339-345.
44. Nieves, D., & Moreno, J. J. (2006). Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3 T6 fibroblast growth. Journal of Lipid Research, 47, 2681-2689. (Pubitemid 44936081)
45. Muthalif, M. M., Benter, I. F., Karzoun, N., Fatima, S., Harper, J., et al. (1998). 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin- dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 12701-12706. (Pubitemid 28483828)
46. Schwartzman, M. L., Falck, J. R., Yadagiri, P., & Escalante, B. (1989). Metabolism of 20-hydroxyeicosatetraenoic acid by cyclooxygenase. Formation and identification of novel endotheliumdependent vasoconstrictor metabolites. The Journal of Biological Chemistry, 264, 11658-11662. (Pubitemid 19185331)
47. Kaduce, T. L., Fang, X., Harmon, S. D., Oltman, C. L., Dellsperger, K. C., et al. (2004). 20-hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells. The Journal of Biological Chemistry, 279, 2648-2656. (Pubitemid 38114252)
48. Moreno, J. J. (2009). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical Pharmacology, 77, 1-10.
49. Stark, K., Dostalek, M., & Guengerich, F. P. (2008). Expression and purification of orphan cytochrome P450 4×1 and oxidation of anandamide. The FEBS Journal, 275, 3706-3717.
50. Chuang, S. S., Helvig, C., Taimi, M., Ramshaw, H. A., Collop, A. H., et al. (2004). CYP2U1, a novel human thymus- and brainspecific cytochrome P450, catalyzes omega- and (omega-1)- hydroxylation of fatty acids. The Journal of Biological Chemistry, 279, 6305-6314. (Pubitemid 38248763)
51. Yang, W., Holmes, B. B., Gopal, V. R., Kishore, R. V., Sangras, B., et al. (2007). Characterization of 14, 15-epoxyeicosatrienoylsulfonamides as 14, 15-epoxyeicosatrienoic acid agonists: Use for studies of metabolism and ligand binding. The Journal of Pharmacology and Experimental Therapeutics, 321, 1023-1031. (Pubitemid 46762683)
52. Spector, A. A. (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. Journal of Lipid Research, 50(Suppl), S52-S56.
53. Karara, A., Wei, S., Spady, D., Swift, L., Capdevila, J. H., et al. (1992). Arachidonic acid epoxygenase: Structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochemical and Biophysical Research Communications, 182, 1320-1325.
54. Spector, A. A., Fang, X., Snyder, G. D., & Weintraub, N. L. (2004). Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Progress in Lipid Research, 43, 55-90. (Pubitemid 37433867)
55. Widstrom, R. L., Norris, A. W., Van Der Veer, J., & Spector, A. A. (2003). Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry, 42, 11762-11767. (Pubitemid 37243637)
56. Liu, Y., Zhang, Y., Schmelzer, K., Lee, T. S., Fang, X., et al. (2005). The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proceedings of the National Academy of Sciences of the United States of America, 102, 16747-16752. (Pubitemid 41688848)
57. Deng, Y., Theken, K. N., & Lee, C. R. (2010). Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. Journal of Molecular and Cellular Cardiology, 48, 331-341.
58. Cowart, L. A., Wei, S., Hsu, M. H., Johnson, E. F., Krishna, M. U., et al. (2002). The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferatoractivated receptor ligands. The Journal of Biological Chemistry, 277, 35105-35112.
59. Fang, X., Hu, S., Watanabe, T., Weintraub, N. L., Snyder, G. D., et al. (2005). Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. The Journal of Pharmacology and Experimental Therapeutics, 314, 260-270. (Pubitemid 41058263)
60. Fang, X., Hu, S., Xu, B., Snyder, G. D., Harmon, S., et al. (2006). 14, 15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha. American Journal of Physiology. Heart and Circulatory Physiology, 290, H55-H63.
61. Folkman, J. (1990). What is the evidence that tumors are angiogenesis-dependent? Journal of the National Cancer Institute, 82, 4-6. (Pubitemid 20020880)
62. McAllister, S. S., & Weinberg, R. A. (2010). Tumor-host interactions: A far-reaching relationship. Journal of Clinical Oncology, 28, 4022-4028.
63. Panigrahy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005). PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biology & Therapy, 4, 687-693. (Pubitemid 41351164)
64. Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432, 332-337. (Pubitemid 39551661)
65. Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine, 285, 1182-1186.
66. Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121, 335-348. (Pubitemid 40692295)
67. Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews. Cancer, 9, 239-252.
68. Lin, E. Y., & Pollard, J. W. (2004). Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 90, 2053-2058. (Pubitemid 38869704)
69. de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews. Cancer, 6, 24-37. (Pubitemid 43053650)
70. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine, 348, 203-213. (Pubitemid 36077915)
71. Clevers, H. (2004). At the crossroads of inflammation and cancer. Cell, 118, 671-674. (Pubitemid 39221727)
72. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006). Inflammation and cancer: How hot is the link? Biochemical Pharmacology, 72, 1605-1621. (Pubitemid 44666739)
73. Seitz, C. S., Lin, Q., Deng, H., & Khavari, P. A. (1998). Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proceedings of the National Academy of Sciences of the United States of America, 95, 2307-2312. (Pubitemid 28145937)
74. Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., et al. (2003). NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature, 421, 639-643. (Pubitemid 36227672)
75. Karin, M. (2009). NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspectives in Biology, 1, a000141.
76. Kaipainen, A., Kieran, M. W., Huang, S., Butterfield, C., Bielenberg, D., et al. (2007). PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE, 2, e260.
77. Panigrahy, D., Kaipainen, A., Kieran, M.W., Huang, S. (2008). PPARs: A Double-Edged Sword in Cancer Therapy? PPAR Res 2008: 350351.
78. Ono, M. (2008). Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Science, 99, 1501-1506.
79. Salcedo, R., Zhang, X., Young, H. A., Michael, N., Wasserman, K., et al. (2003). Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood, 102, 1966-1977. (Pubitemid 37122368)
80. Freedman, R. S., Wang, E., Voiculescu, S., Patenia, R., Bassett, R. L., Jr., et al. (2007). Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clinical Cancer Research, 13, 5736-5744. (Pubitemid 47583898)
81. Ishizuka, T., Cheng, J., Singh, H., Vitto, M. D., Manthati, V. L., et al. (2008). 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. The Journal of Pharmacology and Experimental Therapeutics, 324, 103-110. (Pubitemid 350294158)
82. Guo, A. M., Arbab, A. S., Falck, J. R., Chen, P., Edwards, P. A., et al. (2007). Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acidinduced endothelial cell proliferation. The Journal of Pharmacology and Experimental Therapeutics, 321, 18-27. (Pubitemid 46456964)
83. Dhanasekaran, A., Bodiga, S., Gruenloh, S., Gao, Y., Dunn, L., et al. (2009). 20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology, 296, H777-H786.
84. Chen, P., Guo, M., Wygle, D., Edwards, P. A., Falck, J. R., et al. (2005). Inhibitors of cytochrome P450 4A suppress angiogenic responses. The American Journal of Pathology, 166, 615-624. (Pubitemid 40189056)
85. Ljubimov, A. V., & Grant, M. B. (2005). P450 in the angiogenesis affair: The unusual suspect. The American Journal of Pathology, 166, 341-344. (Pubitemid 40189032)
86. Amaral, S. L., Maier, K. G., Schippers, D. N., Roman, R. J., & Greene, A. S. (2003). CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. American Journal of Physiology. Heart and Circulatory Physiology, 284, H1528-H1535. (Pubitemid 36460763)
87. Sa, G., Murugesan, G., Jaye, M., Ivashchenko, Y., & Fox, P. L. (1995). Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. The Journal of Biological Chemistry, 270, 2360-2366.
88. Jiang, M., Mezentsev, A., Kemp, R., Byun, K., Falck, J. R., et al. (2004). Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circulation Research, 94, 167-174. (Pubitemid 38197448)
89. Miyata, N., Taniguchi, K., Seki, T., Ishimoto, T., Sato-Watanabe, M., et al. (2001). HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. British Journal of Pharmacology, 133, 325-329. (Pubitemid 33027767)
90. Guo, M., Roman, R. J., Falck, J. R., Edwards, P. A., & Scicli, A. G. (2005). Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. The Journal of Pharmacology and Experimental Therapeutics, 315, 526-533. (Pubitemid 41500716)
91. Jacobs, E. R., Zhu, D., Gruenloh, S., Lopez, B., & Medhora, M. (2006). VEGF-induced relaxation of pulmonary arteries is mediated by endothelial cytochrome P-450 hydroxylase. American Journal of Physiology. Lung Cellular and Molecular Physiology, 291, L369-L377. (Pubitemid 44343712)
92. Guo, A. M., Sheng, J., Scicli, G. M., Arbab, A. S., Lehman, N. L., et al. (2008). Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. The Journal of Pharmacology and Experimental Therapeutics, 327, 10-19.
93. Guo, M., Roman, R. J., Fenstermacher, J. D., Brown, S. L., Falck, J. R., et al. (2006). 9 L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N'-(4-butyl- 2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. The Journal of Pharmacology and Experimental Therapeutics, 317, 97-108.
94. Alexanian, A., Rufanova, V. A., Miller, B., Flasch, A., Roman, R. J., et al. (2009). Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Research, 29, 3819-3824.
95. Nithipatikom, K., Isbell, M. A., See, W. A., & Campbell, W. B. (2006). Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Letters, 233, 219-225. (Pubitemid 43327376)
96. Fleming, I. (2008). Vascular cytochrome p450 enzymes: Physiology and pathophysiology. Trends in Cardiovascular Medicine, 18, 20-25.
97. Gross, G. J., Falck, J. R., Gross, E. R., Isbell, M., Moore, J., et al. (2005). Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited. Cardiovascular Research, 68, 18-25. (Pubitemid 41253552)
98. Chaudhary, K. R., Batchu, S. N., Das, D., Suresh, M. R., Falck, J. R., et al. (2009). Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovascular Research, 83, 362-370.
99. Simpkins, A. N., Rudic, R. D., Schreihofer, D. A., Roy, S., Manhiani, M., et al. (2009). Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. The American Journal of Pathology, 174, 2086-2095.
100. Zhang, C., & Harder, D. R. (2002). Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke, 33, 2957-2964. (Pubitemid 35462872)
101. Medhora, M., Daniels, J., Mundey, K., Fisslthaler, B., Busse, R., et al. (2003). Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. American Journal of Physiology. Heart and Circulatory Physiology, 284, H215-H224. (Pubitemid 36076288)
102. Ausprunk, D. H., & Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvascular Research, 14, 53-61.
103. Wang, Y., Wei, X., Xiao, X., Hui, R., Card, J. W., et al. (2005). Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. The Journal of Pharmacology and Experimental Therapeutics, 314, 522-532. (Pubitemid 41043832)
104. Ribatti, D., Vacca, A., Roncali, L., & Dammacco, F. (2000). The chick embryo chorioallantoic membrane as a model for in vivo research on antiangiogenesis. Current Pharmaceutical Biotechnology, 1, 73-82.
105. Michaelis, U. R., Fisslthaler, B., Medhora, M., Harder, D., Fleming, I., et al. (2003). Cytochrome P450 2 C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). The FASEB Journal, 17, 770-772.
106. Yan, G., Chen, S., You, B., & Sun, J. (2008). Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovascular Research, 78, 308-314. (Pubitemid 351556100)
107. Webler, A. C., Popp, R., Korff, T., Michaelis, U. R., Urbich, C., et al. (2008). Cytochrome P450 2 C9-induced angiogenesis is dependent on EphB4. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1123-1129.
108. Zhang, B., Cao, H., & Rao, G. N. (2006). Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3- kinase-Akt signaling in 14, 15-epoxyeicosatrienoic acid-induced angiogenesis. The Journal of Biological Chemistry, 281, 905-914.
109. Cheranov, S. Y., Karpurapu, M., Wang, D., Zhang, B., Venema, R. C., et al. (2008). An essential role for SRC-activated STAT-3 in 14, 15-EET-induced VEGF expression and angiogenesis. Blood, 111, 5581-5591.
110. Yang, S., Lin, L., Chen, J. X., Lee, C. R., Seubert, J. M., et al. (2007). Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. American Journal of Physiology. Heart and Circulatory Physiology, 293, H142-H151. (Pubitemid 47105069)
111. Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., et al. (2000). Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha→hypoxia response element→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research, 60, 6248-6252.
112. Michaelis, U. R., Fisslthaler, B., Barbosa-Sicard, E., Falck, J. R., Fleming, I., et al. (2005). Cytochrome P450 epoxygenases 2 C8 and 2 C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. Journal of Cell Science, 118, 5489-5498. (Pubitemid 43079290)
113. Earley, S., Pastuszyn, A., & Walker, B. R. (2003). Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. American Journal of Physiology. Heart and Circulatory Physiology, 285, H127-H136. (Pubitemid 36736423)
114. Suzuki, S., Oguro, A., Osada-Oka, M., Funae, Y., & Imaoka, S. (2008). Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. Journal of Pharmacological Sciences, 108, 79-88.
115. Webler, A. C., Michaelis, U. R., Popp, R., Barbosa-Sicard, E., Murugan, A., et al. (2008). Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. American Journal of Physiology. Cell Physiology, 295, C1292-C1301. (Pubitemid 352790340)
116. Yang, S., Wei, S., Pozzi, A., & Capdevila, J. H. (2009). The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Archives of Biochemistry and Biophysics, 489, 82-91.
117. Dunn, L. K., Gruenloh, S. K., Dunn, B. E., Reddy, D. S., Falck, J. R., et al. (2005). Chick chorioallantoic membrane as an in vivo model to study vasoreactivity: Characterization of development-dependent hyperemia induced by epoxyeicosatrienoic acids (EETs). The Anatomical Record. Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 285, 771-780. (Pubitemid 41098873)
118. Harris, R. C., Homma, T., Jacobson, H. R., & Capdevila, J. (1990). Epoxyeicosatrienoic acids activate Na+/H+exchange and are mitogenic in cultured rat glomerular mesangial cells. Journal of Cellular Physiology, 144, 429-437.
119. Sellmayer, A., Uedelhoven, W. M., Weber, P. C., & Bonventre, J. V. (1991). Endogenous non-cyclooxygenase metabolites of arachidonic acid modulate growth and mRNA levels of immediate-early response genes in rat mesangial cells. The Journal of Biological Chemistry, 266, 3800-3807. (Pubitemid 21909281)
120. Jiang, J. G., Chen, C. L., Card, J. W., Yang, S., Chen, J. X., et al. (2005). Cytochrome P450 2 J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Research, 65, 4707-4715. (Pubitemid 40740807)
121. Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., et al. (2007). Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Research, 67, 6665-6674. (Pubitemid 47105512)
122. Chen, C., Li, G., Liao, W., Wu, J., Liu, L., et al. (2009). Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics, 329, 908-918.
123. Pozzi, A., Ibanez, M. R., Gatica, A. E., Yang, S., Wei, S., et al. (2007). Peroxisomal proliferator-activated receptor-alphadependent inhibition of endothelial cell proliferation and tumorigenesis. The Journal of Biological Chemistry, 282, 17685-17695. (Pubitemid 47100312)
124. Zagorac, D., Jakovcevic, D., Gebremedhin, D., & Harder, D. R. (2008). Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. Journal of Cerebral Blood Flow and Metabolism, 28, 1431-1439.
125. Nithipatikom, K., Brody, D.M., Tang, A.T., Manthati, V.L., Falck, J.R., et al. (2010). Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci.
126. Pozzi, A., Popescu, V., Yang, S., Mei, S., Shi, M., et al. (2010). The anti-tumorigenic properties of peroxisomal proliferatoractivated receptor alpha are arachidonic acid epoxygenasemediated. The Journal of Biological Chemistry, 285, 12840-12850.
127. Enayetallah, A. E., French, R. A., & Grant, D. F. (2006). Distribution of soluble epoxide hydrolase, cytochrome P450 2 C8, 2 C9 and 2 J2 in human malignant neoplasms. Journal of Molecular Histology, 37, 133-141.
128. Leclerc, J., Tournel, G., Courcot-Ngoubo Ngangue, E., Pottier, N., Lafitte, J. J., et al. (2010). Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. Biochimie, 92, 292-306.
129. Yang, M. D., Wu, C. C., Chiou, S. H., Chiu, C. F., Lin, T. Y., et al. (2003). Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma. Oncology Reports, 10, 271-276.
130. Roques, M., Bagrel, D., Magdalou, J., & Siest, G. (1991). Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells. General Pharmacology, 22, 677-684.
131. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J., & Harris, J. W. (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Research, 54, 5543-5546.
132. Jernstrom, H., Bageman, E., Rose, C., Jonsson, P. E., & Ingvar, C. (2009). CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. British Journal of Cancer, 101, 1817-1823.
133. Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11, 597-607. (Pubitemid 32953585)
134. Isomura, Y., Yamaji, Y., Ohta, M., Seto, M., Asaoka, Y., et al. (2010). A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol.